Collegium Pharmaceutical Inc COLL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Collegium Completes Acquisition of Ironshore Therapeutics
-
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
-
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
-
Collegium Reports Second Quarter 2024 Financial Results
-
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
-
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
Trading Information
- Previous Close Price
- $39.89
- Day Range
- $39.84–42.23
- 52-Week Range
- $20.95–42.23
- Bid/Ask
- $41.91 / $42.05
- Market Cap
- $1.35 Bil
- Volume/Avg
- 555,166 / 425,166
Key Statistics
- Price/Earnings (Normalized)
- 6.97
- Price/Sales
- 3.25
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 5.56%
Company Profile
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 197
- Website
- https://www.collegiumpharma.com
Comparables
Valuation
Metric
|
COLL
|
SIGA
|
ELTP
|
---|---|---|---|
Price/Earnings (Normalized) | 6.97 | 5.97 | 13.23 |
Price/Book Value | 6.25 | 2.97 | 7.18 |
Price/Sales | 3.25 | 2.89 | 6.12 |
Price/Cash Flow | 6.75 | 6.52 | 37.32 |
Price/Earnings
COLL
SIGA
ELTP
Financial Strength
Metric
|
COLL
|
SIGA
|
ELTP
|
---|---|---|---|
Quick Ratio | 0.99 | 5.42 | 2.06 |
Current Ratio | 1.11 | 8.25 | 3.08 |
Interest Coverage | 2.69 | — | 0.99 |
Quick Ratio
COLL
SIGA
ELTP
Profitability
Metric
|
COLL
|
SIGA
|
ELTP
|
---|---|---|---|
Return on Assets (Normalized) | 21.22% | 43.51% | 43.42% |
Return on Equity (Normalized) | 119.33% | 55.68% | 66.45% |
Return on Invested Capital (Normalized) | 32.24% | 55.49% | 56.48% |
Return on Assets
COLL
SIGA
ELTP
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Zoetis Inc Class A
ZTS
| Cyxpkmfrt | Vvpr | $86.1 Bil | |||
Merck KGaA ADR
MKKGY
| Drqlrnbwnx | Yfcmzp | $74.3 Bil | |||
Haleon PLC ADR
HLN
| Zfxkjfqy | Mpqb | $45.9 Bil | |||
Viatris Inc
VTRS
| Qqwrsrfk | Tldl | $13.8 Bil | |||
Dr Reddy's Laboratories Ltd ADR
RDY
| Qhpryqrj | Zvxt | $13.2 Bil | |||
Catalent Inc
CTLT
| Zlrstjcyz | Yywvrcb | $11.0 Bil | |||
Prestige Consumer Healthcare Inc
PBH
| Gfqspbjr | Sdhrc | $3.4 Bil | |||
Perrigo Co PLC
PRGO
| Bclgfpf | Rbwb | $3.4 Bil | |||
Green Thumb Industries Inc
GTBIF
| Fljvczlldy | Gzlb | $2.4 Bil | |||
Curaleaf Holdings Inc
CURLF
| Hjmvsjwx | Zsnzv | $2.2 Bil |